Research graph
References from Virologic Outcomes of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Advanced HIV-1 Disease: A Propensity-Weighted Multicenter Cohort Study. Local targets link to admitted publications; unresolved targets remain external evidence.
HIV epidemiology, prevention, treatment, and implementation strategies for public health
10.1016/s0140-6736(23)01381-8 · 2024 · External reference
Trends and outcomes of late initiation of combination antiretroviral therapy driven by late presentation among HIV-positive Taiwanese patients in the era of treatment scale-up
10.1371/journal.pone.0179870 · 2017 · External reference
The differential impacts of early detection and accelerated antiretroviral therapy on the epidemiologic trend of sexually acquired HIV infection in Hong Kong
10.1371/journal.pone.0274498 · 2022 · External reference
Association of demographics, HCV co-infection, HIV-1 subtypes and genetic clustering with late HIV diagnosis: a retrospective analysis from the Japanese Drug Resistance HIV-1 Surveillance Network
10.1002/jia2.26086 · 2023 · External reference
Unresolved reference
2025 · External reference
Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025
10.1111/hiv.70120 · 2026 · External reference
Antiretroviral Drugs for Treatment and Prevention of HIV in Adults: 2024 Recommendations of the International Antiviral Society-USA Panel
10.1001/jama.2024.24543 · 2025 · External reference
The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review
10.1016/s0140-6736(23)00877-2 · 2023 · External reference
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
10.1016/s0140-6736(17)32299-7 · 2017 · External reference
10.1016/s0140-6736(17)32340-1
10.1016/s0140-6736(17)32340-1 · 2017 · External reference
Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials
10.1016/j.eclinm.2023.101991 · 2023 · External reference
Integrase versus protease inhibitor therapy in advanced HIV disease (LAPTOP): a multicountry, randomised, open-label, non-inferiority trial
2025 · External reference
Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis
10.1093/jac/dkae138 · 2024 · External reference
Meta-Analysis of Efficacy and Safety of Coformulated Bictegravir, Emtricitabine, and Tenofovir Alafenamide Among People Living with HIV
10.1007/s40121-021-00449-z · 2021 · External reference
Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters
10.1016/j.ijantimicag.2023.107016 · 2024 · External reference
Real-world Effectiveness and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Comparison With Other Regimens in People With HIV Starting Therapy With AIDS-Defining Conditions: Results From the CoRIS Cohort-The ACTUAS II Study
10.1093/cid/ciaf162 · 2025 · External reference
Antiretroviral treatment in people living with HIV with late diagnosis initiating ART with DTG/3TC or BIC/TAF/FTC: A real-world cohort analysis
10.1111/hiv.70119 · 2026 · External reference
Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV: Real-world insights from BICSTaR cohorts
10.1111/hiv.13593 · 2024 · External reference
Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in people with HIV in Asia: 24-Month findings from the observational BICSTaR study
10.1097/md.0000000000047358 · 2026 · External reference
Comparison of Virological Efficacy of DTG/ABC/3TG and B/F/TAF Regimens and Discontinuation Patterns in Persons Living with Advanced HIV in the Era of Rapid ART: A Retrospective Multicenter Cohort Study
10.1007/s40121-022-00734-5 · 2023 · External reference
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
10.1056/nejmoa1600693 · 2016 · External reference
Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
10.1001/jama.2016.5148 · 2016 · External reference
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
10.1016/s0140-6736(19)30418-0 · 2019 · External reference
Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study
10.1016/s2352-3018(18)30132-2 · 2018 · External reference
Primary Care Guidance for Providers of Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of America
10.1093/cid/ciae479 · 2024 · External reference
Forty years of HIV infection and AIDS in Taiwan: Reflection on the past and looking toward the future
10.1016/j.jmii.2024.11.003 · 2025 · External reference
Unresolved reference
2020 · External reference
Should viral load thresholds be lowered?: Revisiting the WHO definition for virologic failure in patients on antiretroviral therapy in resource-limited settings
10.1097/md.0000000000003985 · 2016 · External reference
Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
10.1002/sim.6607 · 2015 · External reference
Practical recommendations for reporting Fine-Gray model analyses for competing risk data
10.1002/sim.7501 · 2017 · External reference
Advanced HIV Infection in Treatment-Naive Individuals: Effectiveness and Persistence of Recommended 3-Drug Regimens
10.1093/ofid/ofac018 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes
2023 · External reference
Five-days-on-two-days-off (FOTO) versus daily bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people with HIV: a pilot randomized clinical trial
10.1093/jac/dkaf186 · 2025 · External reference
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group
10.1056/nejm200003303421303 · 2000 · External reference
Relation between HIV viral load and infectiousness: a model-based analysis
10.1016/s0140-6736(08)61115-0 · 2008 · External reference
Impaired CD4+ T-cell and CD4+/CD8+ ratio recovery among people with HIV on antiretroviral therapy: prevalence and risk factors
10.1097/qad.0000000000004456 · 2026 · External reference
CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era
10.1097/qad.0000000000002010 · 2018 · External reference
Comparing the efficacy and safety of a first-line regimen with emtricitabine/tenofovir alafenamide fumarate plus either bictegravir or dolutegravir: Results from clinical practice
10.1016/j.ijantimicag.2023.107040 · 2024 · External reference
Long-Term Evolution of Renal Function Among People with HIV who Received Tenofovir Alafenamide-Containing Antiretroviral Therapy
10.1007/s40121-025-01113-6 · 2025 · External reference
Impact of the initial wave of COVID-19 pandemic in Taiwan on local HIV services: Results from a cross-sectional online survey
10.1016/j.jmii.2022.03.002 · 2022 · External reference
